BioVaxys Technology (FRA:5LB) Net Change in Cash : €0.87 Mil (TTM As of Oct. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

BioVaxys Technology's Net Change in Cash for the three months ended in Oct. 2024 was €-0.19 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Oct. 2024 was €0.87 Mil.

BioVaxys Technology Net Change in Cash Historical Data

The historical data trend for BioVaxys Technology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Net Change in Cash Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Net Change in Cash

Get a 7-Day Free Trial

1.41

-1.27

-0.34

-0.10

0.14

BioVaxys Technology Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Net Change in Cash	Get a 7-Day Free Trial															-	0.66	0.17	0.22	-0.19

BioVaxys Technology Net Change in Cash Calculation

BioVaxys Technology's Net Change in Cash for the fiscal year that ended in Oct. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-1.243	+	-0.705	+	2.087	+	0.001
	=	0.14

BioVaxys Technology's Net Change in Cash for the quarter that ended in Oct. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.677 + 0 + 0.489 + 0

= -0.19

Net Change in Cash for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Net Change in Cash Related Terms
Thank you for viewing the detailed overview of BioVaxys Technology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » Net Change in Cash

Comparable Companies

TSXV:HEM TSX:CSCI TSXV:KNE XCNQ:PREV TSX:RVX TSX:APS XCNQ:BLAB XCNQ:BETR TSXV:SBM XCNQ:GLOW VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

BVAXF:USA BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines